Popular weight-loss drugs may stop prediabetes turning into diabetes, study finds
Popular weight-loss drugs may stop prediabetes turning into diabetes, study finds
Popular weight-loss drugs may stop prediabetes turning into diabetes, study finds
Key points
اہم نکات
मुख्य बातें
- Popular weight-loss drugs may help stop prediabetes from turning into type 2 diabetes, according to a large new study.
- Researchers looked at health records for more than 250,000 adults with prediabetes and obesity and found those taking GLP-1 drugs such as Ozempic and Zepbound were about one and a half times more likely to see their blood sugar return to normal than those taking metformin.
- They also had a 31 percent lower risk of developing type 2 diabetes and a 41 percent lower risk of death from any cause, along with fewer heart attacks and strokes.
- Popular weight-loss drugs may help stop prediabetes from turning into type 2 diabetes, according to a large new study.
- Researchers looked at health records for more than 250,000 adults with prediabetes and obesity and found those taking GLP-1 drugs such as Ozempic and Zepbound were about one and a half times more likely to see their blood sugar return to normal than those taking metformin.
- They also had a 31 percent lower risk of developing type 2 diabetes and a 41 percent lower risk of death from any cause, along with fewer heart attacks and strokes.
- Popular weight-loss drugs may help stop prediabetes from turning into type 2 diabetes, according to a large new study.
- Researchers looked at health records for more than 250,000 adults with prediabetes and obesity and found those taking GLP-1 drugs such as Ozempic and Zepbound were about one and a half times more likely to see their blood sugar return to normal than those taking metformin.
- They also had a 31 percent lower risk of developing type 2 diabetes and a 41 percent lower risk of death from any cause, along with fewer heart attacks and strokes.
Popular weight-loss drugs may help stop prediabetes from turning into type 2 diabetes, according to a large new study. Researchers looked at health records for more than 250,000 adults with prediabetes and obesity and found those taking GLP-1 drugs such as Ozempic and Zepbound were about one and a half times more likely to see their blood sugar return to normal than those taking metformin. They also had a 31 percent lower risk of developing type 2 diabetes and a 41 percent lower risk of death from any cause, along with fewer heart attacks and strokes. The findings, to be presented at the American Heart Association's Scientific Sessions in Chicago, are preliminary and have not yet been peer reviewed.
Popular weight-loss drugs may help stop prediabetes from turning into type 2 diabetes, according to a large new study. Researchers looked at health records for more than 250,000 adults with prediabetes and obesity and found those taking GLP-1 drugs such as Ozempic and Zepbound were about one and a half times more likely to see their blood sugar return to normal than those taking metformin. They also had a 31 percent lower risk of developing type 2 diabetes and a 41 percent lower risk of death from any cause, along with fewer heart attacks and strokes. The findings, to be presented at the American Heart Association's Scientific Sessions in Chicago, are preliminary and have not yet been peer reviewed.
Popular weight-loss drugs may help stop prediabetes from turning into type 2 diabetes, according to a large new study. Researchers looked at health records for more than 250,000 adults with prediabetes and obesity and found those taking GLP-1 drugs such as Ozempic and Zepbound were about one and a half times more likely to see their blood sugar return to normal than those taking metformin. They also had a 31 percent lower risk of developing type 2 diabetes and a 41 percent lower risk of death from any cause, along with fewer heart attacks and strokes. The findings, to be presented at the American Heart Association's Scientific Sessions in Chicago, are preliminary and have not yet been peer reviewed.
Most read
سب سے زیادہ پڑھی گئی
सबसे ज़्यादा पढ़ी गई
- Loading...
Get news in your inbox
خبریں اپنے ان باکس میں حاصل کریں
खबरें अपने इनबॉक्स में पाएं
One email when new stories are published. No spam, unsubscribe anytime.
نئی خبریں شائع ہونے پر ایک ای میل۔ کوئی سپیم نہیں، کسی بھی وقت ان سبسکرائب کریں۔
नई खबरें प्रकाशित होने पर एक ईमेल। कोई स्पैम नहीं, कभी भी अनसब्सक्राइब करें।